Search
Search Results
##search.searchResults.foundPlural##
-
CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia
259PDF: 297Suppl. Files: 58HTML: 59 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2115PDF: 793HTML: 3254 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1797PDF: 830HTML: 226 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1327PDF: 802HTML: 358 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
864PDF: 437HTML: 314 -
Calreticulin mutation survey by high resolution melting method associated with unique presentations in essential thrombocythemic patients CALR mutation survey by HRM in ET patients
1342PDF: 759HTML: 532 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2074PDF: 114HTML: 30 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1636PDF: 1087HTML: 438 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12870PDF: 1715HTML: 4348Cover letter: 215Figure 1: 222 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1329PDF: 1077HTML: 412 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2898PDF: 1875HTML: 3800Pellagatti Fig 1: 237Pellagatti Fig. 2: 231 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2471PDF: 1712HTML: 470 -
-
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1231PDF: 861HTML: 3415 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7789PDF: 2471HTML: 2111Table 1.: 239Table 2.: 247Table 3.: 231Table 4.: 224 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4275PDF: 1979HTML: 5504Table 1: 229 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2045PDF: 1397HTML: 799 -
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1702PDF: 625HTML: 283 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1486PDF: 1362HTML: 111 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1579PDF: 1131HTML: 262 -
COEXISTENCE OF MULTIPLE GENE VARIANTS IN SOME PATIENTS WITH ERYTHROCYTOSES Multiple gene variants in erythrocytosis
903PDF: 1269HTML: 141







